Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Haemonetics stock has delivered a strong 69.0% return over the past year, yet the valuation signals are mixed, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model suggesting the shares trade at a discount, while traditional market multiples lean the other way.
-
Haemonetics has returned 69.0% over the past year, which puts more focus on whether the recent share price strength is backed by fundamentals.
-
Expectations for continued revenue growth from its plasma and vascular closure platforms can support the intrinsic value case. However, any disappointment in future growth or cash flow timing may weigh on what investors are currently willing to pay.
-
The stock passes 3 of 6 valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation on the broader metrics, according to 3 .
The issue now is whether Haemonetics' current share price already reflects this improved outlook, or if the intrinsic value estimate still leaves meaningful upside on the table.
Is Haemonetics a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model projects the cash Haemonetics could generate for shareholders and discounts it back to today. For Haemonetics, the model uses latest twelve month free cash flow of about $291.1 million and assumes that free cash flow continues to grow from current levels rather than shrink. On that basis, the DCF model points to an estimated intrinsic value of about $177 per share.
Compared with the current share price, this implies an intrinsic discount of roughly 48.8%, which screens as undervalued on this method. The recent fiscal Q1 2027 update highlighted higher revenue guidance and ongoing momentum across plasma and interventional technologies, and the market enthusiasm around Haemonetics helps explain why investors are paying closer attention to the cash flow story.
On the DCF numbers alone, Haemonetics stock currently looks undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Haemonetics is undervalued by 48.8%. Track this in your watchlist or portfolio , or discover 51 more high quality undervalued stocks .
Is Haemonetics Getting Expensive on Earnings?
P/E is a useful yardstick for Haemonetics because earnings remain a key focus for many investors in medical equipment stocks. On this measure, Haemonetics trades at about 42.9x earnings, which is above the broader medical equipment industry average of roughly 26.6x. It also sits below the peer group average of about 61.9x, so the stock does not screen as the most expensive in its space, but it is clearly not priced like the lower multiple part of the sector either.
A more tailored fair P/E ratio for Haemonetics, which factors in its business profile and risk, is closer to 32.0x. That is meaningfully below the current 42.9x level, indicating that investors are paying a premium to this benchmark for the stock's earnings today. This contrasts with the DCF view, which points to upside based on cash flows.
On the earnings multiple alone, Haemonetics stock currently screens as overvalued relative to the fair P/E level implied by its fundamentals.
See what the numbers say about this price — find out in our valuation breakdown.
The Haemonetics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Haemonetics sit on the company's Community page and act as the missing link between the DCF and P/E signals above and the assumptions that would need to hold on growth, margins and earnings for either view to make sense. Each narrative ties a fair value estimate to a clear story about Haemonetics' potential catalysts and risks, so you can track over time which version of events is closer to what actually unfolds.
Community views on Haemonetics sit far apart, with one camp focused on product momentum and another fixated on execution and concentration risks.
Bull case: 6% undervalued
"Rapid innovation and increased adoption of advanced plasma collection systems (NexSys with Persona and Express Plus), as well as new software contracts securing ~80% market share, are driving share gains and supporting double-digit organic growth ex-CSL in the plasma segment..."
Read the full Bull Case to see why Haemonetics could be undervalued
Bear case: 38% overvalued
"Although strong innovation in plasma collection platforms and software adoption (especially NexSys and NexLynk) are driving share gains, operational execution risk remains in Vascular Closure and Interventional Technologies, where recent underperformance, increasing competition, and complex customer dynamics could stall expected margin expansion and subdue net margin improvement if not promptly addressed..."
Read the full Bear Case to see why Haemonetics could be overvalued
Do you think there's more to the story for Haemonetics? Head over to our Community to see what others are saying!
The Bottom Line
For Haemonetics, the Discounted Cash Flow (DCF) intrinsic value estimate points to a sizeable discount, while the P/E based view suggests the stock is already priced at a premium to a tailored fair multiple. The mixed value checks underline that neither signal is definitive on its own. The gap mainly comes down to how much weight you put on future cash flows versus what the market is currently willing to pay for earnings in this sector. The real hinge from here is whether Haemonetics can deliver on its revenue and margin ambitions without the execution issues that the bear case highlights.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HAE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
